文献速递免疫规划传染病防控与疫情报告

既往接种两剂CoronaVac者中皮内分次第三剂ChAdOx1 nCoV-19/AZD1222疫苗与标准肌内第三剂的免疫原性和安全性比较:一项随机对照试验

Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial.
PubMed 文献 · Vaccine · 2022-02-21

在泰国曼谷Chulabhorn医院开展的随机对照非劣效试验中,125名已完成两剂CoronaVac接种的成人随机接受标准肌内、20%标准剂量皮内或40%标准剂量皮内AZD1222第三剂;两种皮内分次剂量组的免疫原性均达到非劣效标准,局部不良事件在皮内组更常见但多为轻至中度。

要点

  • 皮内分次第三剂AZD1222的免疫原性非劣效于标准肌内第三剂。
  • 皮内组局部不良事件更常见,但多为轻至中度。
  • 该接种策略可能有助于节约疫苗供应。

核心结论

  • 在既往接种CoronaVac者中,皮内分次第三剂AZD1222非劣效于标准肌内第三剂。
  • 皮内分次第三剂相关不良事件包括轻至中度局部注射部位反应。
  • 该接种策略可能有助于节约疫苗供应。

研究设计与样本

  • 非劣效随机对照试验,2021年8月9日至2021年8月13日在泰国曼谷Chulabhorn医院入组。
  • 纳入标准为年龄18岁及以上且至少2个月前已完成两剂CoronaVac接种。
  • 采用区组随机化将参与者分为三组:标准剂量肌内组(IM)、20%标准剂量皮内组(ID1)、40%标准剂量皮内组(ID2)。
  • 共125名参与者被随机分组:IM组n=41,ID1组n=41,ID2组n=43。
  • ID1组有1名参与者在接种后第14天前失访。

主要发现

  • 抗受体结合域抗体几何平均比值(95%置信区间)在ID1组为0.94(0.80-1.09),在ID2组为1.28(0.95-1.74)。
  • 两个皮内组的免疫原性均达到非劣效标准。
  • 局部不良事件在皮内组比IM组更常见,但严重程度大多为轻至中度。

关键数值与推荐

  • 主要终点为接种后14天ID1/ID2组与IM组抗受体结合域抗体几何平均比值。
  • 非劣效界值原文未报告。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The CoronaVac vaccine is widely used in Thailand to combat the coronavirus disease 2019 (COVID-19) pandemic. The limited immunogenicity of this vaccine is a concern, especially because of expanding delta variant outbreaks. A third boost may enhance antiviral immune responses. METHODS: This non-inferiority randomized controlled trial evaluated the immunogenicity and safety of an intradermal (ID) fractional third dose of AZD1222 vaccine compared with those of a standard intramuscular (IM) third dose. Participants were enrolled from August 9, 2021 to August 13, 2021 at Chulabhorn Hospital, Bangkok, Thailand. The eligibility criteria were age 18 years or older and prior two-dose Coronavac vaccination completed at least 2 months previously. Participants were randomly assigned to one of three groups by block randomization: (i) standard dose by IM administration (IM), (ii) 20% of the standard dose ID (ID1), or (iii) 40% of the standard dose ID (ID2). The primary endpoint was the geometric mean ratio of anti-receptor binding domain antibody in the ID1/ID2 vs. the IM groups 14 days post-vaccination. RESULTS: A total of 125 participants were randomized (IM, n = 41; ID1, n = 41; and ID2, n = 43). One participant was lost to follow-up by day 14 post-vaccination in the ID1 group. The geometric mean ratio (95% confidence interval) of anti-receptor binding domain antibody was 0.94 (0.80-1.09) in the ID1 group and 1.28 (0.95-1.74) in the ID2 group. Immunogenicity in both ID groups met the non-inferiority criteria. Local adverse events were more common in the ID groups than in the IM group but were mostly mild to moderate in severity. CONCLUSION: An ID fractional third dose of AZD1222 was non-inferior to a standard IM third dose among individuals previously vaccinated with CoronaVac. Adverse events associated with the ID fractional third dose included mild to moderate local site reactions. This vaccination strategy may help conserve vaccine supply.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tawinprai K, Siripongboonsitti T, Porntharukchareon T, et al. Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial. Vaccine. 2022. PMID: 35210118. doi:10.1016/j.vaccine.2022.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。